"Pfizer's VELSIPITY Receives EU Approval for Inflammatory Bowel Disease Treatment"
Pfizer's drug Velsipity, used to treat ulcerative colitis, has been approved by the European Commission for patients aged 16 or older who did not respond well to previous treatments. The approval, based on successful late-stage trials, allows the drug to be available in all 27 EU countries. With an estimated 2.6 million people in Europe living with ulcerative colitis, Velsipity is expected to compete with Bristol Myers Squibb's Zeposia and has also sought regulatory approvals in other countries.